HTATIP2 and hepatocellular carcinoma: In conclusion, our results signify that the combination of HTATIP2 and MVD predicts the converse survival of HCC with or without sorafenib intervention and that patients with high HTATIP2 expression and low MVD level may not benefit from this drug.